Leukodystrophy
0
Pipeline Programs
19
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
19 companies ranked by most advanced pipeline stage
Human BioSciencesWV - Martinsburg
1 programThe Nosology and Etiology of Leukodystrophies of Unknown CausesN/A
Genome & CompanyKorea - Suwon
1 programThe Nosology and Etiology of Leukodystrophies of Unknown CausesN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
MyrtelleThe Myelin Disorders Biorepository Project
Genome & CompanyThe Nosology and Etiology of Leukodystrophies of Unknown Causes
Clinical Trials (2)
Total enrollment: 12,076 patients across 2 trials
The Myelin Disorders Biorepository Project
Start: Dec 2016Est. completion: Dec 203012,000 patients
N/ARecruiting
The Nosology and Etiology of Leukodystrophies of Unknown Causes
Start: Apr 2009Est. completion: Aug 201876 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 12,076 patients
19 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.